The Oncology Drugs segment focuses on the research, development, and commercialization of innovative therapies for various cancers. This includes the development of novel drug candidates, such as CD228-targeted ADC drugs, and the advancement of existing treatments like Lipusu, CMNa, and Tiandida. Research and development activities involve preclinical studies, clinical trials, and regulatory submissions to ensure patient safety and efficacy. The segment leverages advanced technologies, including liposome technology, to improve drug delivery and efficacy. The patient impact is significant, as these drugs address critical unmet needs in cancer treatment, improving survival rates and quality of life. Luye Pharma's market positioning is strengthened by its focus on innovative therapies and strategic partnerships. Future opportunities include expanding the product pipeline and entering new markets. Regulatory and clinical aspects are crucial, with rigorous testing and approval processes. Partnerships with research institutions and other pharmaceutical companies are essential for accelerating drug development and market access.

This segment is dedicated to the development, manufacturing, and marketing of medications for neurological and psychiatric disorders. The segment's research and development efforts focus on creating innovative treatments for conditions such as schizophrenia, bipolar disorder, and Alzheimer's disease. Technologies employed include advanced formulation techniques and drug delivery systems, such as transdermal patches. The segment addresses significant patient needs by providing therapies that improve cognitive function, manage symptoms, and enhance the quality of life for individuals with CNS disorders. Luye Pharma's market position is strengthened by its established products like Seroquel and Seroquel XR, as well as its focus on innovative delivery methods. Future growth opportunities include expanding the product portfolio and entering new markets. Regulatory compliance and clinical trials are critical components of this segment, ensuring the safety and efficacy of the medications. Partnerships with healthcare providers and research institutions are essential for advancing treatment options and improving patient outcomes.

This segment focuses on the development, production, and commercialization of drugs targeting cardiovascular diseases and metabolic disorders, including diabetes. Research and development activities include the formulation of new drugs and the improvement of existing therapies. Technologies used include advanced drug delivery systems and formulation techniques. The segment addresses significant patient needs by providing treatments for conditions such as high cholesterol, diabetes, and other cardiovascular and metabolic diseases. Luye Pharma's market position is enhanced by its existing products and strategic partnerships. Future opportunities include expanding the product pipeline and entering new markets. Regulatory compliance and clinical trials are essential for ensuring the safety and efficacy of the medications. Partnerships with healthcare providers and research institutions are crucial for advancing treatment options and improving patient outcomes.

This segment focuses on the development, manufacturing, and marketing of medications for gastrointestinal disorders. Research and development activities include the formulation of new drugs and the improvement of existing therapies. Technologies used include advanced drug delivery systems and formulation techniques. The segment addresses significant patient needs by providing treatments for conditions such as diarrhea and upper digestive tract hemorrhage. Luye Pharma's market position is enhanced by its existing products and strategic partnerships. Future opportunities include expanding the product pipeline and entering new markets. Regulatory compliance and clinical trials are essential for ensuring the safety and efficacy of the medications. Partnerships with healthcare providers and research institutions are crucial for advancing treatment options and improving patient outcomes.